iNPHORM Publications & Disseminations

hypo-lower-banner_880x300.jpg

Published Articles

Manuscripts

Ratzki-Leewing AA, Ryan BL, Buchenberger JD, Dickens JW, Black JE, Harris SB. COVID-19 hinterland: surveilling the self-reported impacts of the pandemic on diabetes management in the USA (cross-sectional results of the iNPHORM study). BMJ Open. 2021 Sep 2;11(9):e049782. doi: 10.1136/bmjopen-2021-04978.

Ratzki-Leewing A, Ryan BL, Zou G, Webster-Bogaert S, Black JE, Stirling K, Timcevska K, Khan N, Buchenberger JD, Dickens JW, Harris SB. Predicting real-world hypoglycemia risk in American adults with type 1 or 2 diabetes mellitus prescribed insulin and/or secretagogues: Protocol for a prospective, 12-wave internet-based panel survey with email support (the iNPHORM study, USA). JMIR Res Protoc. 2022 Jan 6. doi: 10.2196/33726. Epub ahead of print. PMID: 35025756.

Abstracts

  • Alexandria Ratzki-Leewing, Jason E. Black, Bridget L. Ryan, Guangyong Zou, Stewart B. Harris, London, ON, Canada. Why Some Americans Use Healthcare Following Severe Hypoglycemia, And Why Some Do Not: Baseline Results Of The iNPHORM Study. Diabetes 2021 Jun;70(Supplement 1) 347-P https://doi.org/10.2337/db21-347-P

  • Ratzki-Leewing A, Harris S, Ryan, B Zou G. Real-world estimates of severe hypoglycemia and associated healthcare utilization in the US: baseline results of the iNPHORM study. Diabetes Technology & Therapeutics Vol 23, Supplement 2, 2021 pg A-140 http://doi.org/10.1089/dia.2021.2525.abstracts

  • Ratzki-Leewing A, Harris S, Black J, Stirling K, Zou G, Ryan B. Second-generation basal insulin analogues: first-choice in reducing real-world severe hypoglycemia (baseline results of the iNPHORM study, USA) Diabetes Technology & Therapeutics Vol 23, Supplement 2, 2021 pg A-89 to A-90. http://doi.org/10.1089/dia.2021.2525.abstracts

  • Ratzki-Leewing A, Ryan BL, Zou GY, Au NH, Webster-Bogaert S, Harris S. Investigating novel predictions of hypoglycemia occurrence using real-world models (iNPHORM Study): a study protocol. Morressier. 2019. doi.org/10.26226/MORRESSIER.5DC53540EA541D6CA8493.

  • Ratzki-Leewing A, Harris S, Black J, Stirling K, Zou G, Ryan B. Second-generation basal insulin analogues: first-choice in reducing real-world severe hypoglycemia (baseline results of the iNPHORM study, USA) Diabetes Technology & Therapeutics Vol 23, Supplement 2, 2021 pg A-89 to A-90. http://doi.org/10.1089/dia.2021.2525.abstracts

  • Ratzki-Leewing A, Harris SB, Zou G, Ryan BL. Real-world estimates of severe hypoglycaemia and associated healthcare utilisation in the US: baseline results of the iNPHORM study Diabetologia. 2020.63(Suppl.1):750P, S363. doi.org/10.1007/s00125-020-05221-5

Posters